Neil Kumar Sells 326,932 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 326,932 shares of the business’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $36.29, for a total value of $11,864,362.28. Following the transaction, the chief executive officer now directly owns 5,371,515 shares of the company’s stock, valued at $194,932,279.35. The trade was a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, November 19th, Neil Kumar sold 27,389 shares of BridgeBio Pharma stock. The shares were sold at an average price of $22.41, for a total value of $613,787.49.

BridgeBio Pharma Trading Down 1.3 %

Shares of NASDAQ BBIO traded down $0.49 during midday trading on Thursday, reaching $35.97. 2,154,592 shares of the company were exchanged, compared to its average volume of 2,899,899. The stock has a market cap of $6.80 billion, a P/E ratio of -14.93 and a beta of 1.05. The stock has a fifty day simple moving average of $29.64 and a 200 day simple moving average of $27.10. BridgeBio Pharma, Inc. has a 1 year low of $21.62 and a 1 year high of $41.04.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Oppenheimer began coverage on shares of BridgeBio Pharma in a report on Thursday, October 3rd. They issued a “market perform” rating on the stock. Evercore ISI raised their price objective on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Leerink Partners dropped their target price on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Scotiabank lifted their price target on BridgeBio Pharma from $45.00 to $48.00 and gave the stock a “sector outperform” rating in a report on Monday, November 25th. Finally, Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, BridgeBio Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $48.08.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Values First Advisors Inc. acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter worth $57,000. CWM LLC increased its position in BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after purchasing an additional 1,964 shares during the period. Advisors Asset Management Inc. raised its stake in shares of BridgeBio Pharma by 56.1% during the 3rd quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock worth $117,000 after buying an additional 1,645 shares in the last quarter. Amalgamated Bank boosted its stake in shares of BridgeBio Pharma by 24.7% in the second quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock valued at $123,000 after buying an additional 962 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in BridgeBio Pharma by 17.7% during the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company’s stock worth $135,000 after acquiring an additional 801 shares during the period. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.